1. Home
  2. TUSK vs PYXS Comparison

TUSK vs PYXS Comparison

Compare TUSK & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mammoth Energy Services Inc.

TUSK

Mammoth Energy Services Inc.

HOLD

Current Price

$3.39

Market Cap

137.3M

Sector

Energy

ML Signal

HOLD

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$3.73

Market Cap

141.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TUSK
PYXS
Founded
2014
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
137.3M
141.3M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
TUSK
PYXS
Price
$3.39
$3.73
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
168.9K
939.3K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
102.32
3.03
EPS
0.11
N/A
Revenue
$44,292,000.00
$13,858,000.00
Revenue This Year
$383.90
N/A
Revenue Next Year
N/A
$7,043.98
P/E Ratio
$26.73
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.72
$0.97
52 Week High
$3.92
$5.55

Technical Indicators

Market Signals
Indicator
TUSK
PYXS
Relative Strength Index (RSI) 55.19 72.22
Support Level $2.54 $3.67
Resistance Level $3.54 $4.58
Average True Range (ATR) 0.14 0.29
MACD 0.03 0.08
Stochastic Oscillator 94.90 99.67

Price Performance

Historical Comparison
TUSK
PYXS

About TUSK Mammoth Energy Services Inc.

Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes rental services, infrastructure services, natural sand proppant services, accommodation services, and drilling services.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: